On September 22, CANSINOBIO rose 5.25% in regular trading, trading at HK$29.68/share, with turnover of approximately HK$69.16 million. The rally was primarily fueled by sustained momentum in the mRNA cancer vaccine theme, combined with improving fundamentals from the company's mid-term results.
On the catalyst front, Moderna's personalized mRNA cancer vaccine intismeran achieved the primary endpoint in its Phase III INTerpath-001 trial, which institutional research described as a platform-level revaluation event. CLSA noted that CANSINOBIO's development pathway and antigen design are broadly comparable to Moderna's, with a key differentiator being its three-component lipid nanoparticle delivery system, which may support stronger cellular immune responses. The company previously signed a strategic cooperation framework agreement with deepGeneAI to co-develop personalized mRNA therapeutic cancer vaccines targeting gastrointestinal solid tumors and rare cancers.
Separately, CANSINOBIO's interim results showed revenue of approximately RMB 547 million, up 46.1% year-over-year, with operating profit reaching RMB 27.54 million, marking a turnaround from prior losses. Overseas revenue surged 4,724% to RMB 152 million. On September 16, the company granted 287,400 restricted A-shares to 19 employees, signaling management confidence.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments